Website unlawfully selling versions of Novo Nordisk weight loss drugs gets USFDA warning
The U.S. Food and Drug Administration (USFDA) said on tuesday it had issued a warning against a website called ozempen.com for illegally selling versions of weight-loss drugs of Novo Nordisk.
Increasing demand for Novo’s Ozempic, Eli Lilly’s Mounjaro, and other GLP-1 drugs that aid in weight loss has led to a burgeoning global market for counterfeit versions.
The FDA said the website was offering unapproved versions of obesity and diabetes drugs Ozempic and Wegovy.
“These products are only available pursuant to a prescription from a licensed practitioner,” as per Reuters report , the health regulator said.
Last month, the World Health Organization issued warnings on fake drugs claiming to contain the active ingredient found in Ozempic and Wegovy.
Lilly and Novo have sued several entities to stop them from selling products claiming to contain the active ingredients tirzepatide and semaglutide that are used in their respective popular diabetes and weight-loss drugs.
Facebook Comments
